The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial

Adv Ther. 2022 Oct;39(10):4632-4644 doi: 10.1007/s12325-022-02269-0

In the latest study by Curtis, et al. guselkumab treatment regimens improved general HRQoL as measured by the EQ-5D-5L Index and EQ-VAS. In reaching this conclusion investigators aimed to determine the minimal important difference for both instruments and to understand the associations between patient-reported EQ-5D-5L Index and EQ-VAS scores as well as key PsA clinical features.

In addition to their central conclusion this investigation found that PsA-associated impairment in HRQoL was associated with increased psoriasis symptoms, fatigue, TJC, SJC, pain, and CRP level. This suggests that the treatment of multiple PsA domains with guselkumab may lead not only to improvement in clinical signs and symptoms but also to enhanced overall patient HRQoL outcomes.